<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01106014</url>
  </required_header>
  <id_info>
    <org_study_id>AC-065A302</org_study_id>
    <nct_id>NCT01106014</nct_id>
  </id_info>
  <brief_title>Selexipag (ACT-293987) in Pulmonary Arterial Hypertension</brief_title>
  <acronym>GRIPHON</acronym>
  <official_title>A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of
      selexipag on time to first morbidity or mortality event in patients with pulmonary arterial
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1, 2009</start_date>
  <completion_date type="Actual">October 1, 2014</completion_date>
  <primary_completion_date type="Actual">April 1, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake</measure>
    <time_frame>Up to 7 days after end of double-blind treatment (maximum: 4.3 years)</time_frame>
    <description>Time from randomization to the first occurrence of a morbidity event or death (all causes) was analyzed with the Kaplan-Meier method (event-free KM estimates at different time points).
Morbidity event was defined as any of the following events confirmed by the Critical Event committee:
Hospitalization for worsening of pulmonary arterial hypertension (PAH),
Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy,
Initiation of parenteral prostanoid therapy or chronic oxygen therapy due to worsening of PAH,
Disease progression which was defined by a decrease in 6-minute walk distance from baseline (&gt;=15%, confirmed by a 2nd test on a different day) combined with worsening of WHO FC for patients belonging to WHO FC II/III at baseline, or combined with the need for additional PAH-specific therapy for patients belonging to WHO FC III/IV at baseline.
Note: The number of patients at risk decreased over time but this cannot be captured below</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD) at Trough</measure>
    <time_frame>Week 26</time_frame>
    <description>The 6-minute walk distance test (6MWD) is a non-encouraged test performed in a 30 m long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. If the patient was used to taking bronchodilators before a walk, he/she was given them 5 to 30 min before the test. Also if the patient was on chronic oxygen therapy, oxygen was given at their standard rate during the test. Absolute change from baseline to Week 26 in 6MWD was measured at trough, i.e., either on the next day after the last study drug administration or at least 12 hours after study drug administration if on the same day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Worsening From Baseline to Week 26 in Modified NYHA/WHO Functional Class (WHO FC)</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1156</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selexipag is up-titrated from Day 1 to Week 12 to each patient's maximum tolerated dose in the range of 200-1600 µg twice a day (b.i.d.) in 200 µg steps starting with one 200 µg oral tablet on Day 1. From Day 2 onwards, a b.i.d. dose regimen with an interval of approximately 12 hours is followed. If this dose (selexipag 200 μg b.i.d.) is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg. Up-titration is followed by a stable maintenance treatment period from Week 12 onwards, up to Week 26, at the maximum tolerated dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo is administered orally with a dosing interval of approximately12 h. A (mock) up-titration scheme is followed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selexipag</intervention_name>
    <description>Selexipag 200 µg tablets</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ACT-293987</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets matching selexipag</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients 18-75 years old, with symptomatic PAH

          -  PAH belonging to the following subgroups of the updated Dana Point Clinical
             Classification Group 1 (Idiopathic, or Heritable, or Drug or toxin induced, or
             Associated (APAH) with Connective tissue disease, Congenital heart disease with simple
             systemic-to-pulmonary shunt at least 1 year after surgical repair, or HIV infection)

          -  Documented hemodynamic diagnosis of PAH by right heart catheterization, performed at
             any time prior to Screening

          -  Six minute walk distance (6MWD) between 50 and 450 m at Screening within 2 weeks prior
             to the Baseline Visit

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients with pulmonary hypertension (PH) in the Updated Dana Point Classification
             Groups 2-5, and PAH Group 1 subgroups that are not covered by the inclusion criteria

          -  Patients who have received prostacyclin or its analogs within 1 month before Baseline
             Visit, or are scheduled to receive any of these compounds during the trial

          -  Patients with moderate or severe obstructive lung disease

          -  Patients with moderate or severe restrictive lung disease

          -  Patients with moderate or severe hepatic impairment (Child-Pugh B and C)

          -  Patients with documented left ventricular dysfunction

          -  Patients with severe renal insufficiency

          -  Patients with BMI &lt;18.5 Kg/m2

          -  Patients who are receiving or have been receiving any investigational drugs within 1
             month before the Baseline Visit

          -  Acute or chronic impairment (other than dyspnea), limiting the ability to comply with
             study requirements, in particular with 6MWT

          -  Recently conducted or planned cardio-pulmonary rehabilitation program based on
             exercise training

          -  Psychotic, addictive or other disorder limiting the ability to provide informed
             consent or to comply with study requirements

          -  Life expectancy less than 12 months

          -  Females who are lactating or pregnant or plan to become pregnant during the study

          -  Known hypersensitivity to any of the excipients of the drug formulations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aline Frey</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Arizona, Clinical and Translational Science (CATS) Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center (La Jolla)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GLVA Healthcare Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis, UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LIU Center for Pulmonary Hypertension</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502-2006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung Health &amp; Sleep Emhancement Center, LLC</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Health Sciences University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912-3135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Clinical Research</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clarian North Hospital</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentuckiana Pulmonary Associates</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Health Science Center - New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital - Pulmonary Critical Care Unit</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital-Pulmonary Critical Care Unit</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine / Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Isreal Medical Center-Department of Pulmonary Medicine</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center, Weiler Division</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center, Pediatric Cardiology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Clinical Trial Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219-2906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Pulmonary Associates, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Bucks Specialists</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2386</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas-Houston Health Center Department of Pulmonary &amp; Critical Care</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital-Department of Medicine</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital - Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion y Prevencion Cardiovascular (CIPREC)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1119ACN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Otamendi y Miroli S.A.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1121ABL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico-Pneumology</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio San Jose</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425DUH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Privado Centro Medico de Cordoba S.A.</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto De Cardiologia de Corrientes</name>
      <address>
        <city>Corrientes</city>
        <zip>W3400AMZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital / Heart and Lung Transplant Unit</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital Lung Transplant, Thoracic Department</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital, Cardiovascular Investigation Unit (CVIU)</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre, Pulmonary Hypertension, c/- Cardiology</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital, Centre for Clinical Research</name>
      <address>
        <city>Hobart</city>
        <zip>TAS 7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital Autoimmune Resource and Research Centre</name>
      <address>
        <city>New Lambton</city>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital, Department of Respiratory and Sleep Medicine</name>
      <address>
        <city>Parkville</city>
        <zip>VIC 3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna and AKH Cardiology</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Republican Scientific-Practical Center &quot;Cardiology&quot;</name>
      <address>
        <city>Minsk</city>
        <zip>220036</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minsk City Hospital No. 9</name>
      <address>
        <city>Minsk</city>
        <zip>220116</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minsk Regional Clinical Hospital of the Red Banner of Labour</name>
      <address>
        <city>Minsk</city>
        <zip>223040</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulb Erasme, Cardiology</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg - Pneumologie</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital - Children's Centre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital General Juif (Jewish General Hospital)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional del Torax Teaching Dept</name>
      <address>
        <city>Santiago</city>
        <zip>7500691</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Tabancura- Cardiology Unit</name>
      <address>
        <city>Santiago</city>
        <zip>7650018</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile-Departmento De Enfermedades Cardiovasculares</name>
      <address>
        <city>Santiago</city>
        <zip>8330074</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital, Rheumatology Department</name>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute &amp; Fuwai Hospital-Pulmonary Vascular Center</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital, Cardiology Department</name>
      <address>
        <city>Guangzhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital, Rheumatology Department</name>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital, Cardiology Department</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital, Department of Pulmonary Circulation</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardio Infantil</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Clinica Shaio</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gen Faculty Hosp Prague Cardiology Clin</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital , Cardiology</name>
      <address>
        <city>Arhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Hjertemedicinsk klinik - Cardiology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Pradel Lyon - Dpt Pneumology</name>
      <address>
        <city>Bron cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Cote de Nacre - Dpt Pneumology</name>
      <address>
        <city>Caen Cedex</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp A. Beclere - Dept Pulmo &amp; Resp Intensive Care</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Huriez - Dpt Internal Medecine</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Civil - Dpt Pneumology</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Larrey - Dpt Pneumology</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK Kliniken Köpenick</name>
      <address>
        <city>Berlin</city>
        <zip>12559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus, Medizinische Klinik1-Pneumologie/MK1-A13</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Justus-Liebig-Universität Gießen Zentrum für Innere Medizin Medizinische Klinik II&quot;</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Greifswald / Klinik für Innere Medizin B</name>
      <address>
        <city>Greifswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover / Klinik für Pneumologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik am Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin (Kardiologie, Pneumologie, Angiologie und Intensivmedizin)&quot;</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Pneumologie und Allergologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Löwenstein gGmbH, Medizinische Klinik 1, Pneumologie - Kardiologie</name>
      <address>
        <city>Löwenstein</city>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinkum Regensburg / Innere Medizin II</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onasseio Cardiosurgical Hospital</name>
      <address>
        <city>Athens</city>
        <zip>176 74</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály&quot;</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Semmelweis Egyetem, Pulmonológiai Klinika&quot;</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Egészségügyi Járóbeteg Központ Kardiológiai Intézete - Debrecen</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Pécsi Tudományegyetem Klinikai Központ,</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Szegedi Tudományegyetem ÁOK Szent-Györgyi Albert Klinikai Központ, II. sz. Belgyógyászati klinika és Kardiológiai központ&quot;</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanjivani Hospitals - Department of Cardiology</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals, Chennai</name>
      <address>
        <city>Chennai</city>
        <zip>600006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frontier Lifeline Hospitals, Dr KM Cherian Heart Foundation, Chennai</name>
      <address>
        <city>Chennai</city>
        <zip>600101</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARE Hospitals Nampally, Cardiology Dep. Hyderabad</name>
      <address>
        <city>Hyderabad</city>
        <zip>500001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Indraprastha Hospitals</name>
      <address>
        <city>New Delhi</city>
        <zip>110076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Miscordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center, Pulmonary Unit</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonology Institute, Hadassah University Hospital at Ein Karem</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Centre - Pulmonology</name>
      <address>
        <city>Petach Tikvah</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical - Pulmonary Institute</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Med Ctr -Pulmonology</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola-Malpighi - Dipartimento Cardio-Toraco-Vascolare</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda Università Degli Studi di Napoli - Azienda Universitaria Policlinico - Dipartimento Assistenziale di medicina Generale, Angiologia, Endocrinologia, Epatogastroenterologia e Reumatologia - Unità Operativa di Reumatologia</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISMETT - Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione - Dipartimento di Medicina - Divisione di Pneumologia</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gil Medical Centre</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Nathional University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System Dept of Cardiology</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center, Division of Cardiology</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;The Catholic University of Korea, Seoul St. Mary's Hospital Department of Cardiology&quot;</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jantung Negara (National Heart Institute)</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubrian</name>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiologia (INC) Ignacio Chavez</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum / Afdeling longziekten, secretariaat 4A 48</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht / Department of Pulmonary Diseases</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis afdeling Longziekten</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum Rotterdam afdeling longziekten</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Edgardo Rebagliati / Unidad de Investigacion Cardiologia 2</name>
      <address>
        <city>Lima</city>
        <zip>11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Enfermedades Respiratorias Clinica San Gabriel</name>
      <address>
        <city>Lima</city>
        <zip>32</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Uniwersyteckie Centrum Kliniczne II Klinika Kardiologii i Elektroterapii Serca&quot;</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Instytut Kardiologii Collegium Medium UJ Krakowski Szpital Specjalistyczny im Jana Pawła II Klinika Chorób Serca i Naczyń&quot;</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Instytut Gruźlicy i Chorób Płuc Klinika Chorób Wewnętrznych Klatki Piersiowej&quot;</name>
      <address>
        <city>Warszawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Wojewódzki Specjalistyczny Szpital im. dr Władysława Biegańskiego Oddział Kardiologiczny, II Katedra i Klinika Kardiologii UM&quot;</name>
      <address>
        <city>Łódź</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Institutul de Pneumologie &quot;Marius Nasta&quot;, I. Clinica de Pneumoftiziologie&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>050159</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Spitalul Clinic de Pneumoftiziologie Iasi Sectia Clinica I de Pneumoftiziologie&quot;</name>
      <address>
        <city>Iasi</city>
        <zip>700115</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Medical Institution City Hospital #5</name>
      <address>
        <city>Barnaul</city>
        <zip>656045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital # 1</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kemerovo Cardiology Dispensary / Kemerovo Regional Hospital</name>
      <address>
        <city>Kemerovo</city>
        <zip>650044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute of Pulmonology of the Federal Medical and Biological Agency of Russia</name>
      <address>
        <city>Moscow</city>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution, &quot;Institute fo Rheumatology of RAMS&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institution of the Clinical Cardiology named after A. L. Myaskinov</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited liability company, Consultative diagnostic centre Healthy Joints</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V. A. Almazov Institute of Cardiology, Russian Ministry of Healthcare and Social Development / Medical Treatment and Rehabilitation Complex</name>
      <address>
        <city>St Petersburg</city>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Scientific Research Institute of Tomsk Scientific Center of RAMs, Siberian Branch / Cardiovascular Surgery Department</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tomsk Regional Clinical Hospital/ Pulmonology Unit</name>
      <address>
        <city>Tomsk</city>
        <zip>634063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Klinički Centar Srbije, Klinika za pulmologiju&quot;</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Kliničko-bolnički centar Zemun, Kardiološko odeljenje&quot;</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Centre (NHC) Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>168752</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Národný ústav srdcových a cievnych chorôb, a.s. - NÚSCH a.s.</name>
      <address>
        <city>Bratislava</city>
        <zip>833 48</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Vall D'Hebron - Barcelona - Pneumology</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic-Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset, Kardiologi</name>
      <address>
        <city>Goteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital, Cardiology</name>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umeå University Hospital, Cardiology (Umeå)</name>
      <address>
        <city>Umea</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala Akademiska Sjukhuset, Kardiologkliniken 50F</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel Division of Pneumology</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Bern, Clinic for Pneumology (Inselspital)</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUG Hôpitaux Universitaires de Genève; Pneumology, PAH</name>
      <address>
        <city>Genève 14</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen Klinik für Pneumologie</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital (KVGH)</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital / Department of Surgery</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital, Khon Kaen University, Division of Allergy-Immunology and Rheumatology, Department of Medicine</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Çukurova Üniversitesi Tıp Fakültesi Kardiyoloji Anabilim Dalı</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Üniversitesi Kardiyoloji Enstitisü</name>
      <address>
        <city>Istanbul</city>
        <zip>34096</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara Üniversitesi Tip Fakultesi Kardiyoloji Anabilim Dali</name>
      <address>
        <city>Istanbul</city>
        <zip>34899</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylül Üniversitesi Tıp Fakültesi Kardiyoloji Anabilim Dalı</name>
      <address>
        <city>İzmir</city>
        <zip>35210</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Dnipropetrovsk State Medical Academy, Municipal Institution &quot;&quot;Dnipropetrovsk Regional Clinic Diagnostic Center&quot;&quot;</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49060</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Care Municipal Institution, City Clinical Hospital #13</name>
      <address>
        <city>Kharkiv</city>
        <zip>61124</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Institution &quot;F.H. Yanovski Phthisiology and Pulmonology National Institute Under Ukrainian Academy of Medical Sciences&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Clinical Hospital</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee - Pulm Vascular Unit</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 4HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free &amp; Ucms Rheumatology Unit</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <results_reference>
    <citation>Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.</citation>
    <PMID>26699168</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2010</study_first_submitted>
  <study_first_submitted_qc>April 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2010</study_first_posted>
  <results_first_submitted>February 2, 2016</results_first_submitted>
  <results_first_submitted_qc>February 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 1, 2016</results_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>PAH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selexipag</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1351 patients were screened from 181 sites in 39 countries worldwide. Of these, 1156 were randomized</recruitment_details>
      <pre_assignment_details>Screening assessments were performed up to a maximum of 28 days before baseline</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SELEXIPAG</title>
          <description>During the 12-week titration phase, treatment was initiated at 200 μg twice daily (b.i.d.) and up-titrated weekly in 200 μg b.i.d. increments to the maximum tolerated dose (MTD) for each individual patient but not above 1600 μg b.i.d. At Week 12, patients continued the treatment at their individual MTD up to Week 26. Thereafter the dose could be up-titrated at scheduled visits if needed for patients receiving a dose &amp;lt; 1600 μg b.i.d. The dose could be decreased at any time in case of tolerability issues.</description>
        </group>
        <group group_id="P2">
          <title>PLACEBO</title>
          <description>Matching placebo was administered orally following the same administration schedule as described for selexipag</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="574"/>
                <participants group_id="P2" count="582"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="252"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="285"/>
                <participants group_id="P2" count="330"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Morbidity or Mortality primary endpoint</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="242"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Selexipag</title>
          <description>During the 12-week titration phase, treatment was initiated at 200 μg twice daily (b.i.d.) and up-titrated weekly in 200 μg b.i.d. increments to the maximum tolerated dose (MTD) for each individual patient but not above 1600 μg b.i.d. At Week 12, patients continued the treatment at their individual MTD up to Week 26. Thereafter the dose could be up-titrated at scheduled visits if needed for patients receiving a dose &amp;lt; 1600 μg b.i.d. The dose could be decreased at any time in case of tolerability issues.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo was administered orally following the same administration schedule as described for selexipag</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="574"/>
            <count group_id="B2" value="582"/>
            <count group_id="B3" value="1156"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.2" spread="15.19"/>
                    <measurement group_id="B2" value="47.9" spread="15.55"/>
                    <measurement group_id="B3" value="48.1" spread="15.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="457"/>
                    <measurement group_id="B2" value="466"/>
                    <measurement group_id="B3" value="923"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasion / White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="376"/>
                    <measurement group_id="B2" value="375"/>
                    <measurement group_id="B3" value="751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Western Europe &amp; Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eastern Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latin America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PAH etiology</title>
          <description>Number of patients in each PAH etiology category</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Idiopathic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="312"/>
                    <measurement group_id="B2" value="337"/>
                    <measurement group_id="B3" value="649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heritable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Associated with connective tissue disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assoc. with corrected (&gt;=12Mo) congenital shunts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Associated with drug or toxin exposure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Associated with HIV infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified NYHA/WHO Functional class (FC)</title>
          <description>Number of patients in each NYHA/WHO Functional class (FC) at screening. The WHO FC ranges from I to IV, with higher ranges indicating more severe functional restrictions</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>FC I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FC II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="274"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B3" value="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FC III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="314"/>
                    <measurement group_id="B3" value="607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FC IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PAH medications at baseline</title>
          <description>Number of patients receiving PAH background medication at the time of study drug start</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endothelin Receptor Agonists (ERA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphodiesterase type 5 inhibitors (PDE5-I)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERA and PDE5I in combination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since PAH diagnosis</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.9" lower_limit="0.0" upper_limit="37.3"/>
                    <measurement group_id="B2" value="1.1" lower_limit="0.0" upper_limit="38.9"/>
                    <measurement group_id="B3" value="1.0" lower_limit="0.0" upper_limit="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6-minute walk distance (6MWD) at baseline</title>
          <units>Meters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="376" lower_limit="90" upper_limit="482"/>
                    <measurement group_id="B2" value="369" lower_limit="50" upper_limit="515"/>
                    <measurement group_id="B3" value="372" lower_limit="50" upper_limit="515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake</title>
        <description>Time from randomization to the first occurrence of a morbidity event or death (all causes) was analyzed with the Kaplan-Meier method (event-free KM estimates at different time points).
Morbidity event was defined as any of the following events confirmed by the Critical Event committee:
Hospitalization for worsening of pulmonary arterial hypertension (PAH),
Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy,
Initiation of parenteral prostanoid therapy or chronic oxygen therapy due to worsening of PAH,
Disease progression which was defined by a decrease in 6-minute walk distance from baseline (&gt;=15%, confirmed by a 2nd test on a different day) combined with worsening of WHO FC for patients belonging to WHO FC II/III at baseline, or combined with the need for additional PAH-specific therapy for patients belonging to WHO FC III/IV at baseline.
Note: The number of patients at risk decreased over time but this cannot be captured below</description>
        <time_frame>Up to 7 days after end of double-blind treatment (maximum: 4.3 years)</time_frame>
        <population>The primary endpoint was analyzed using the full analysis set, which includes all randomized patients evaluated according to the study drug to which they have been randomized (intention-to treat analysis set).</population>
        <group_list>
          <group group_id="O1">
            <title>Selexipag</title>
            <description>During the 12-week titration phase, treatment was initiated at 200 μg twice daily (b.i.d.) and up-titrated weekly in 200 μg b.i.d. increments to the maximum tolerated dose (MTD) for each individual patient but not above 1600 μg b.i.d. At Week 12, patients continued the treatment at their individual MTD up to Week 26. Thereafter the dose could be up-titrated at scheduled visits if needed for patients receiving a dose &amp;lt; 1600 μg b.i.d. The dose could be decreased at any time in case of tolerability issues</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo was administered orally following the same administration schedule as described for selexipag</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake</title>
          <description>Time from randomization to the first occurrence of a morbidity event or death (all causes) was analyzed with the Kaplan-Meier method (event-free KM estimates at different time points).
Morbidity event was defined as any of the following events confirmed by the Critical Event committee:
Hospitalization for worsening of pulmonary arterial hypertension (PAH),
Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy,
Initiation of parenteral prostanoid therapy or chronic oxygen therapy due to worsening of PAH,
Disease progression which was defined by a decrease in 6-minute walk distance from baseline (&gt;=15%, confirmed by a 2nd test on a different day) combined with worsening of WHO FC for patients belonging to WHO FC II/III at baseline, or combined with the need for additional PAH-specific therapy for patients belonging to WHO FC III/IV at baseline.
Note: The number of patients at risk decreased over time but this cannot be captured below</description>
          <population>The primary endpoint was analyzed using the full analysis set, which includes all randomized patients evaluated according to the study drug to which they have been randomized (intention-to treat analysis set).</population>
          <units>Percentage of patients free of events</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="574"/>
                <count group_id="O2" value="582"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>KM estimate at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" lower_limit="88.5" upper_limit="93.4"/>
                    <measurement group_id="O2" value="81.7" lower_limit="78.2" upper_limit="84.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KM estimate at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" lower_limit="79.5" upper_limit="86.1"/>
                    <measurement group_id="O2" value="70.6" lower_limit="66.6" upper_limit="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KM estimate at Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" lower_limit="71.2" upper_limit="79.2"/>
                    <measurement group_id="O2" value="61.3" lower_limit="56.8" upper_limit="65.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KM estimate at Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" lower_limit="63.0" upper_limit="72.4"/>
                    <measurement group_id="O2" value="53.9" lower_limit="49.0" upper_limit="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KM estimate at Month 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" lower_limit="56.3" upper_limit="66.9"/>
                    <measurement group_id="O2" value="49.3" lower_limit="44.2" upper_limit="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KM estimate at Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2" lower_limit="51.7" upper_limit="64.1"/>
                    <measurement group_id="O2" value="41.7" lower_limit="35.2" upper_limit="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis was performed on the Full Analysis Set by a one-sided unstratified log-rank test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>one-sided p-value</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD) at Trough</title>
        <description>The 6-minute walk distance test (6MWD) is a non-encouraged test performed in a 30 m long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. If the patient was used to taking bronchodilators before a walk, he/she was given them 5 to 30 min before the test. Also if the patient was on chronic oxygen therapy, oxygen was given at their standard rate during the test. Absolute change from baseline to Week 26 in 6MWD was measured at trough, i.e., either on the next day after the last study drug administration or at least 12 hours after study drug administration if on the same day.</description>
        <time_frame>Week 26</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Selexipag</title>
            <description>During the 12-week titration phase, treatment was initiated at 200 μg twice daily (b.i.d.) and up-titrated weekly in 200 μg b.i.d. increments to the maximum tolerated dose (MTD) for each individual patient but not above 1600 μg b.i.d. At Week 12, patients continued the treatment at their individual MTD up to Week 26. Thereafter the dose could be up-titrated at scheduled visits if needed for patients receiving a dose &amp;lt; 1600 μg b.i.d. The dose could be decreased at any time in case of tolerability issues</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo was administered orally following the same administration schedule as described for selexipag</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD) at Trough</title>
          <description>The 6-minute walk distance test (6MWD) is a non-encouraged test performed in a 30 m long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. If the patient was used to taking bronchodilators before a walk, he/she was given them 5 to 30 min before the test. Also if the patient was on chronic oxygen therapy, oxygen was given at their standard rate during the test. Absolute change from baseline to Week 26 in 6MWD was measured at trough, i.e., either on the next day after the last study drug administration or at least 12 hours after study drug administration if on the same day.</description>
          <population>Full analysis set</population>
          <units>Meters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="574"/>
                <count group_id="O2" value="582"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6MWD at baseline - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="376" lower_limit="90" upper_limit="482"/>
                    <measurement group_id="O2" value="369" lower_limit="50" upper_limit="515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6MWD at Week 26- Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370" lower_limit="0" upper_limit="617"/>
                    <measurement group_id="O2" value="346" lower_limit="0" upper_limit="650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6MWD Change from baseline at Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="-448" upper_limit="260"/>
                    <measurement group_id="O2" value="-9" lower_limit="-438" upper_limit="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-parametric ANCOVA with 6MWD as covariate at baseline. Missing values were imputed based on the following imputation rules: 1) if patient was unable to walk at week 26, 0 meter was imputed, 2) if rule 1 did not apply, the second lowest observed 6MWD value (10 meters) at Week 26 was imputed. Missing values were imputed for 21.6% of the subjects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <p_value_desc>One-sided p-value of the nonparametric ANCOVA, adjusted for 6-minute walk distance at baseline</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>12</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>24</ci_upper_limit>
            <estimate_desc>Point estimate and 2-sided 99% CI for location shift using the HodgesLehmann method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Worsening From Baseline to Week 26 in Modified NYHA/WHO Functional Class (WHO FC)</title>
        <time_frame>Week 26</time_frame>
        <population>Full analysis set. Patients with WHO FC IV at baseline were excluded from this analysis as they could not shift to a worse category</population>
        <group_list>
          <group group_id="O1">
            <title>Selexipag</title>
            <description>During the 12-week titration phase, treatment was initiated at 200 μg twice daily (b.i.d.) and up-titrated weekly in 200 μg b.i.d. increments to the maximum tolerated dose (MTD) for each individual patient but not above 1600 μg b.i.d. At Week 12, patients continued the treatment at their individual MTD up to Week 26. Thereafter the dose could be up-titrated at scheduled visits if needed for patients receiving a dose &amp;lt; 1600 μg b.i.d. The dose could be decreased at any time in case of tolerability issues</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo was administered orally following the same administration schedule as described for selexipag</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Worsening From Baseline to Week 26 in Modified NYHA/WHO Functional Class (WHO FC)</title>
          <population>Full analysis set. Patients with WHO FC IV at baseline were excluded from this analysis as they could not shift to a worse category</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="574"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8"/>
                    <measurement group_id="O2" value="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>It was assumed that the probabilities for absence of worsening in WHO FC at Week 26 were the same for both treatment groups</non_inferiority_desc>
            <p_value>0.2843</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel test stratified by WHO FC at baseline. For patients with missing NYHA/WHO FC at Week 26, the NYHA/WHO FC is considered as having worsened from baseline at Week 26. Missing values were imputed for 18.3% of subjects .</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio, log</param_type>
            <param_value>1.161</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.811</ci_lower_limit>
            <ci_upper_limit>1.664</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline up to up to 7 days after end of treatment (EOT)</time_frame>
      <desc>Median duration of exposure to study drug was 70.7 weeks (range: 0.3–216.7 weeks) in the selexipag group and 63.7 weeks (range: 0.7–192.0 weeks) in the placebo group</desc>
      <group_list>
        <group group_id="E1">
          <title>Selexipag</title>
          <description>This group includes patients who received at least one dose of selexipag. One subject who was randomized to placebo received a single dose of 8 tablets of selexipag due to an error in the dispensation of the medication bottle. Therefore, this patient was assigned to the selexipag group in the safety analysis set.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>This group includes patients who received at least one dose of placebo. Four patients who were randomized to placebo never received the drugs and another patient received selexipag by mistake (see Selexipag group for more details). Therefore, these patients were excluded from the placebo group in the safety analysis set.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="252" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="272" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>IDIOPATHIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ACUTE RIGHT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="575"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ATRIAL THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>BRADYARRHYTHMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CHRONIC RIGHT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>COR PULMONALE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>COR PULMONALE ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>COR PULMONALE CHRONIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CYANOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" events="42" subjects_affected="34" subjects_at_risk="575"/>
                <counts group_id="E2" events="49" subjects_affected="41" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>AUTOIMMUNE THYROIDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>BASEDOW'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CHOROIDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>MACULOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ANAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ENTEROCELE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ANGIODYSPLASIA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE POLYP</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>NECROTISING COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL VARICES HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SIGMOIDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="575"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>EXERCISE TOLERANCE DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SUDDEN CARDIAC DEATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HEPATIC CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HEPATIC MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HEPATORENAL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>NODULAR REGENERATIVE HYPERPLASIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LUNG TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SARCOIDOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SECONDARY IMMUNODEFICIENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ABSCESS INTESTINAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ABSCESS ORAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>APPENDICITIS PERFORATED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ATYPICAL PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="575"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CATHETER SITE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CYSTITIS ESCHERICHIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DIABETIC GANGRENE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HEPATITIS C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LYMPHANGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PARAINFLUENZAE VIRUS INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PAROTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PILONIDAL CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="575"/>
                <counts group_id="E2" events="30" subjects_affected="25" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS CHRONIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>TRACHEOBRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ACETABULUM FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>BRAIN HERNIATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CRANIOCEREBRAL INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>GINGIVAL INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>JAW FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LIP INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>MULTIPLE INJURIES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PUBIS FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FUME INHALATION DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>TRAUMATIC FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>VACCINATION COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>VASCULAR PROCEDURE COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>BRAIN NATRIURETIC PEPTIDE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CARDIAC INDEX DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CATHETERISATION CARDIAC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>INVESTIGATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>OXYGEN SATURATION DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERIAL PRESSURE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERIAL WEDGE PRESSURE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>RED BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>TRANSPLANT EVALUATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>WALKING DISTANCE TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DYSLIPIDAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ELECTROLYTE IMBALANCE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>FLUID RETENTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIC SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CHONDROCALCINOSIS PYROPHOSPHATE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CREST SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CRYSTAL ARTHROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>MIXED CONNECTIVE TISSUE DISEASE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>OSTEOPOROTIC FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>POLYMYOSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>STILL'S DISEASE ADULT ONSET</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SYSTEMIC SCLEROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>BREAST CANCER RECURRENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMANGIOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>COLORECTAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DIFFUSE LARGE B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LYMPHANGIOSIS CARCINOMATOSA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>AGEUSIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ATAXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>AUTONOMIC NERVOUS SYSTEM IMBALANCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CEREBELLAR SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DEMYELINATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIC UNCONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>MENTAL IMPAIRMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PARKINSON'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>POST HERPETIC NEURALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="575"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>THALAMIC INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>VOCAL CORD PARALYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>PREGNANCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>RUPTURED ECTOPIC PREGNANCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ALCOHOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SCHIZOAFFECTIVE DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SOMNAMBULISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>STRESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PRERENAL FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ANURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LUPUS NEPHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>OLIGURIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="575"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>URETHRAL STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>CERVICAL DYSPLASIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CYSTOCELE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ENDOMETRIOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST RUPTURED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE LUNG INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="575"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ORGANISING PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ORTHOPNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERIAL HYPERTENSION</sub_title>
                <counts group_id="E1" events="106" subjects_affected="83" subjects_at_risk="575"/>
                <counts group_id="E2" events="183" subjects_affected="127" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERY DILATATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PULMONARY HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PULMONARY INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PULMONARY VENO-OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>RESPIRATORY GAS EXCHANGE DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>TACHYPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DERMATOMYOSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PAIN OF SKIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SCLERODERMA ASSOCIATED DIGITAL ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>TELANGIECTASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>BARIATRIC GASTRIC BALLOON INSERTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>BLADDER NECK SUSPENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CARDIAC PACEMAKER INSERTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CARDIOVERSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CERVICAL CONISATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CHOLECYSTECTOMY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DRUG THERAPY CHANGED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>GLAUCOMA SURGERY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HAEMODIALYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>LUNG TRANSPLANT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>MASTECTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>NASAL SEPTAL OPERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SALPINGECTOMY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SKIN NEOPLASM EXCISION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>STEM CELL TRANSPLANT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>TURBINECTOMY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>URETHRAL OPERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>EXTREMITY NECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HAEMODYNAMIC INSTABILITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIC SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PERIPHLEBITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS SUPERFICIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>VASCULITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>VENA CAVA THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>VENOUS INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="544" subjects_at_risk="575"/>
                <counts group_id="E2" subjects_affected="486" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="53" subjects_affected="43" subjects_at_risk="575"/>
                <counts group_id="E2" events="37" subjects_affected="28" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="40" subjects_affected="32" subjects_at_risk="575"/>
                <counts group_id="E2" events="41" subjects_affected="31" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="54" subjects_affected="44" subjects_at_risk="575"/>
                <counts group_id="E2" events="37" subjects_affected="29" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="39" subjects_affected="34" subjects_at_risk="575"/>
                <counts group_id="E2" events="38" subjects_affected="32" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="375" subjects_affected="242" subjects_at_risk="575"/>
                <counts group_id="E2" events="137" subjects_affected="109" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="265" subjects_affected="192" subjects_at_risk="575"/>
                <counts group_id="E2" events="136" subjects_affected="107" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="143" subjects_affected="103" subjects_at_risk="575"/>
                <counts group_id="E2" events="53" subjects_affected="48" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="33" subjects_affected="29" subjects_at_risk="575"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="575"/>
                <counts group_id="E2" events="54" subjects_affected="39" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="54" subjects_affected="46" subjects_at_risk="575"/>
                <counts group_id="E2" events="72" subjects_affected="58" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="90" subjects_affected="77" subjects_at_risk="575"/>
                <counts group_id="E2" events="138" subjects_affected="100" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="46" subjects_affected="42" subjects_at_risk="575"/>
                <counts group_id="E2" events="49" subjects_affected="41" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="105" subjects_affected="75" subjects_at_risk="575"/>
                <counts group_id="E2" events="95" subjects_affected="63" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="100" subjects_affected="72" subjects_at_risk="575"/>
                <counts group_id="E2" events="119" subjects_affected="79" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="30" subjects_affected="24" subjects_at_risk="575"/>
                <counts group_id="E2" events="34" subjects_affected="30" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="38" subjects_affected="34" subjects_at_risk="575"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="82" subjects_affected="62" subjects_at_risk="575"/>
                <counts group_id="E2" events="57" subjects_affected="44" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="36" subjects_affected="34" subjects_at_risk="575"/>
                <counts group_id="E2" events="38" subjects_affected="35" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="120" subjects_affected="90" subjects_at_risk="575"/>
                <counts group_id="E2" events="37" subjects_affected="34" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="142" subjects_affected="95" subjects_at_risk="575"/>
                <counts group_id="E2" events="62" subjects_affected="46" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PAIN IN JAW</sub_title>
                <counts group_id="E1" events="188" subjects_affected="148" subjects_at_risk="575"/>
                <counts group_id="E2" events="38" subjects_affected="36" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="111" subjects_affected="85" subjects_at_risk="575"/>
                <counts group_id="E2" events="106" subjects_affected="85" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="649" subjects_affected="374" subjects_at_risk="575"/>
                <counts group_id="E2" events="261" subjects_affected="189" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="575"/>
                <counts group_id="E2" events="42" subjects_affected="34" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="67" subjects_affected="56" subjects_at_risk="575"/>
                <counts group_id="E2" events="87" subjects_affected="67" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="100" subjects_affected="79" subjects_at_risk="575"/>
                <counts group_id="E2" events="143" subjects_affected="110" subjects_at_risk="577"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERIAL HYPERTENSION</sub_title>
                <counts group_id="E1" events="64" subjects_affected="46" subjects_at_risk="575"/>
                <counts group_id="E2" events="141" subjects_affected="84" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" events="80" subjects_affected="69" subjects_at_risk="575"/>
                <counts group_id="E2" events="31" subjects_affected="29" subjects_at_risk="577"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical trial disclosure desk</name_or_title>
      <organization>Actelion Pharmaceuticals Ltd</organization>
      <email>clinical-trials-disclosure@actelion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

